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Abstract
Purpose The current incidence of cancer in the world is
14 million cases in 2012, with a mortality rate of 8.2
million in that year. The incidence of cancer in Spain
exceeds 215,000 cases a year, and survival rates are the
highest when compared to those of our neighbouring
countries. Among the reasons for the steady decrease in
cancer mortality rates in Spain, two causes must be high-
lighted: the increasing efficacy of treatment and prevention
measures. It is important evaluate the opportunity of early
detection and prevention in these tumors.
Methods We have reviewed the evidence published in
the most prevalent tumors. The evidence levels described
in this paper are based on the GRADE system.
Results We show the recommendations about primary
and secondary prevention in breast cancer, cervical cancer,
colorectal cancer, prostate cancer and lung cancer.
Conclusion The diffusion of these preventive tools can
reduce the incidence of cancer and increase the number of
early diagnostics in the most prevalent tumors.
Keywords Prevention  Primary and secondary  Cancer 
SEOM
Introduction
The current incidence of cancer in the world is 14 million
cases in 2012, with a mortality rate of 8.2 million in that
year [1]. The incidence of cancer in Spain exceeds 215,000
cases a year, and survival rates are the highest when
compared to those of our neighbouring countries. Among
the reasons for the steady decrease in cancer mortality rates
in Spain, two causes must be highlighted: the increasing
efficacy of treatment and prevention measures.
The present study analyses tumours in which prevention
has shown to be of use, or is at least being debated as a
useful possibility. Both primary and secondary prevention
measures have been assessed.
The evidence levels described in this paper are based on
the GRADE system (Table 1).
Breast cancer
Breast cancer (BC) is the most frequent cancer among
women and the first cause of death among European
women. In 2012, the estimated age-adjusted annual inci-
dence in the European Union was 82.1/100,000 and the
mortality 15.5/100,000 (GLOBOCAN). The incidence has
increased after the introduction of mammography screen-
ing and the ageing of the population and the mortality has
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decreased because of improved treatments and early
detection. The result of this trend is a longer survival rate.
The focus of this guideline is summarising the current
evidence on prevention of BC in women at average risk of
developing BC. In this subgroup, women must have no
symptoms, no history of invasive BC, ductal or lobular
carcinoma in situ or atypical hyperplasia, no family history
in a first-degree relative, no suggestion/evidence of a
hereditary syndrome and no history of chest wall radiation.
For women at increased risk, please consult the SEOM
clinical guideline for hereditary cancer.
Primary prevention
The main risk factors for BC (personal, familiar and
reproductive factors and age) cannot be changed. Regular
physical activity beginning in the early childhood, weight
control and alcohol intake reduction are strategies that can
decrease the probability to develop this disease. The use of
pharmacologic interventions for BC reduction is not rec-
ommended for women at average risk.
Secondary prevention
Early detection through screening remains the primary tool
available to healthy women in preventing the development
of BC, and thus reducing BC mortality.
Mammography
Screening mammography is currently the best available
method to detect BC at an early stage and the only that is
associated with significant reduction in mortality [3].
Expert groups and medical societies recommend routine
screening with mammography for women aged 50 and
older [4–6]. However, there is controversy about women in
their 40s, due to lower risk of BC, smaller reduction in
mortality compared with older women and higher impact
of harms related to screening mammography (false-
positive and overdiagnosis rates) [7]. The decision to start
screening before age 50 years should be an individual one
and should take into account patient context, including the
patient’s values regarding specific benefits and harms.
There is insufficient current evidence to assess the addi-
tional benefits and harms of screening mammography in
women aged 75 years or older. The appropriate interval for
screening mammography is 2 years (Table 2).
Magnetic resonance imaging (MRI)
There are no data evaluating whether screening women at
average risk of breast cancer using MRI scans reduce mor-
tality as compared with mammography or no screening.
Breast examinations
No evidence is found to show that clinical breast exami-
nation (CBE) or breast self-examination (BSE) reduces the
risk of mortality.
BC screening remains a subject of intense debate.
Although mammography remains the gold standard, it also
has limitations and recent studies raise questions of
potential harms [3]. Besides, as treatment of clinically
detected disease improves, the benefit of the screening
probably diminishes. Optimal BC screening will probably
require a personalised approach, with application of tech-
nologies best suited to the individual‘s age and risk.
Cervical cancer
Primary prevention
The most important cause of cervical cancer is persistent
human papillomavirus (HPV) infection, in particular the
oncogenic subtypes such as HPV 16 and 18. Randomised
clinical trials have shown that HPV 16 and 18 vaccination
is highly effective in preventing moderate-grade cervical
Table 2 Screening recommendations for BC in women at average risk
Population Women aged 40–49 Women aged 50–69 Women aged 70–74
Mammography Individualise, every 2 years
2C
Routinely, every 2 years
2B




















Words in bold identify the main recommendations
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dysplasia or worse pathology (CIN2?) among women not
previously exposed to these types of HPV [8, 9]. There
currently are 2 HPV vaccines available: a quadrivalent
vaccine that protects against infection by HPV types 6, 11,
16 and 18 and a bivalent vaccine that protects against HPV
types 16 and 18. These vaccines will be more cost-effective
if given prior to initiating sexual activity, and the priority
target population is young adolescent females
Secondary prevention
The Papanicolaou (Pap) smear is the method of choice in
screening for cervical cancer. In the last years testing for
HPV has been proposed as an adjunct or alternative to Pap
test screening. Both have been compared in several large
trials and the findings do not suggest a clearly dominant
screening strategy. Cervical cancer screening should begin
at age 21 years; women should discontinue screening after
age 65 years if they have no history of CIN2? within the
last 20 years and have had adequate negative prior
screening (3 consecutive negative cytology tests or 2
consecutive negative co-tests within the previous 10 years,
with the most recent test occurring within the last 5 years)
Recommendations
• Routine HPV vaccination is recommended mainly for
females aged 11–12 years, but also for females aged
13–18 to catch up those who have not been previously
vaccinated or completed their vaccine series (grade
1A). Standard screening for cervical cancer should
continue in vaccinated women.
• For women aged 21–29 years, screening with cytology
alone every 3 years is recommended (grade 1B). HPV
testing should not be used to screen women in this age
group.
• Women aged 30–65 years should be screened with the
combination of cytology and HPV testing every
5 years, but it is also acceptable the screening with
cytology alone every 3 years (grade 1A).
• Women who have undergone total hysterectomy with
removal of the cervix and have no history of
CIN2? should not be screened for cervical cancer
(grade 1B) (Table 3).
Prostate cancer
Primary prevention
There is strong evidence indicating an association between
androgens and the risk of prostate cancer. The 5a-reductase
inhibitors that are used to treat benign prostatic hyperplasia
block the conversion of testosterone to dihydrotestosterone
and have shown to reduce the risk of prostate cancer [10].
Moreover, several randomised trials using antioxidants such
as selenium and vitamin E have failed to demonstrate benefit.
Secondary prevention
Currently, best evidence supports the use of serum pros-
tate-specific antigen (PSA) for the early detection of
prostate cancer. However, many experts continue to rec-
ommend digital rectal examination (DRE) for screening, as
some clinically significant cancers may potentially be
missed using a serum PSA cut point alone. The true ben-
efits of prostate cancer screening are unclear despite the
results from two large randomised trials [11, 12] investi-
gating whether PSA testing reduces prostate cancer mor-
tality. In addition, early detection results in identification of
many men with indolent disease that could not benefit from
immediate treatment. False positive results of PSA and
DRE can contribute to patient anxiety, increased costs and
potential complications associated with unnecessary biop-
sies. For these reasons, the patient and the physician should
discuss the risks and potential benefits prior to testing.
Table 3 Recommendations for the screening of cervical and prostate cancer
Cancer site Population Recommended screening method
Cervix (women) Aged \21 years No screening
Aged 21–29 years Cytology alone every 3 years
Aged 30–65 years HPV and cytology every 5 years (preferred) or Cytology alone every 3 years (acceptable)
Aged [65 years No screening if adequate negative prior screening and no history of CIN2?
After hysterectomy No screening
Prostate (men) Aged 50–70 years PSA ± DRE
PSA \3 ng/mL Repeat every 1–2 years
PSA 3–4 ng/mL Individualised risk assessment
PSA C4 ng/mL Consider biopsy or repeat test in 6–12 m
HPV human papillomavirus, CIN2 cervical intraepithelial neoplasia grade 2, PSA serum prostate-specific antigen, DRE digital rectal examination
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Recommendations
• Asymptomatic men with a PSA \3.0 ng/mL who are
regularly screened with PSA or are anticipating
undergoing annual PSA screening for early detection of
prostate cancer may benefit from a discussion of both
the risks and benefits of 5a-reductase inhibitors (grade
2B).
• Screening is recommended with PSA with or without
DRE for well-informed men aged 50–70 years (grade
1A).
• For men with PSA \3 ng/mL, the test should be
repeated every 1–2 years (grade 1B).
• For men whose PSA is [4 ng/mL or those with DRE
suspicious for cancer at any PSA level, a biopsy should
be considered. If not biopsy is performed, repeat testing
in 6–12 months (grade 1B). Percent-free PSA may be
assessed in selected patients with PSA values between
4 and 10 ng/mL.
• For PSA levels between 3 and 4 ng/mL, physicians
should consider an individualised risk assessment that
incorporates other risk factors. These factors include
age, family history, ethnicity, DRE or PSA kinetics
(grade 2C) Table 3.
Colorectal cancer
Colorectal cancer (CRC) is the most frequent type of
cancer among the population. Mortality rates have
decreased in past years, mainly as a result of the imple-
mentation of CRC screening programmes in many indus-
trialised countries.
The different known aspects of primary and secondary
prevention, as well as the evidence levels described in the
scientific literature, are discussed in the following
paragraphs.
Primary prevention [13–16]
• Consumption of red meat, processed meat and cooked
meat that is very well done or has been prepared in
direct contact with the source of heat should be mod-
erate (Grade B recommendation).
• A low-fat diet that is high in fibre, fruit and vegetables
is advisable (Grade B), although published results are
not conclusive. A diet that is high in milk and dairy
products is also recommended (Grade B).
• Folate, calcium and vitamin D intake must be adequate
(Grade B), but not provided in the form of dietary
supplements.
• Antioxidant supplements should not be taken.
• Physical exercise and avoidance of excess weight and
obesity must be encouraged to prevent CRC (Grade B).
• NSAIDs and aspirin should not be taken systematically
to prevent CRC (Grade B), nor should hormone
treatment be administered (Grade A).
CRC screening recommendations in the average risk
population [15] (Table 4)
Individuals of 50 years of age and over, with no additional
risk factors, are considered to be at average risk for CRC.
Individuals of under 50 years of age, with no specific risk
factors, are considered to be at low risk for CRC, and do
not require screening. However, individuals with personal
and/or familial CRC risk factors should be considered for
screening or observation, based on their personal back-
ground and medical history (colonic polyposis, Lynch
syndrome, family history of CRC, ulcerative colitis, etc.)
[15, 16].
• Tests for the detection of hidden blood in faeces (SOH)
are a useful tool, and must be considered in CRC
screening programmes (Grade A).
Table 4 CRC screening recommendations in average risk populations
Recommendation Evidence
Tests for the detection of hidden blood in faeces (SOH) are a useful tool, and must be considered in CRC screening programmes A
Population screening programmes should include a quantitative SOHi (immunohistochemical) detection test with a positive cutoff
point that guarantees optimal balance between sensitivity and specificity, based on available endoscopic resources
B
Opportunistic screening procedures should include SOHi detection tests, although a high-sensitivity SOHg (Guayaco) test could also
be used
B
Flexible sigmoidoscopy is an efficient test that must be considered in CRC screening, at intervals of at least five years B
Sigmoidoscopic detection of distal adenomatous polyps requires full colonoscopy (Grade A). This is not the case with hyperplastic
polyps
B
A combined detection strategy using SOHg tests and flexible sigmoidoscopy should not be considered in CRC screening B
Colonoscopies should be performed at intervals of at least 10 years B
CT-scan colonoscopy should not be considered in CRC screening until more assessments are available on the benefits, costs and
acceptability of the technique
B
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• Population screening programmes should include a
quantitative SOHi (immunohistochemical) detection
test with a positive cutoff point that guarantees optimal
balance between sensitivity and specificity, based on
available endoscopic resources (Grade B).
• Opportunistic screening procedures should include
SOHi detection tests, although a high-sensitivity SOHg
(Guayaco) test could also be used (Grade B).
• Flexible sigmoidoscopy is an efficient test that must be
considered in CRC screening, at intervals of at least
five years (Grade B).
• Sigmoidoscopic detection of distal adenomatous polyps
requires full colonoscopy (Grade A). This is not the
case with hyperplastic polyps (Grade B).
• A combined detection strategy using SOHg tests and
flexible sigmoidoscopy should not be considered in
CRC screening (Grade B).
• Colonoscopies should be performed at intervals of at
least 10 years (Grade B).
• CT-scan colonoscopy should not be considered in CRC
screening until more assessments are available on the
benefits, costs and acceptability of the technique (Grade B).
Recommendations for population-wide CRC [13, 16]
screening programmes (Table 5)
• CRC screening should be offered to all individuals with
no risk factors as from the age of 50. In accordance
with guidelines established in our milieu (European
Union, Spain and its regions), SOH detection tests
should be performed every two years in men and
women of 50–74 years of age (Grade A).
• Screening tests in population programmes should be
based on a quantitative SOHi analysis with a positive
cutoff point that guarantees an optimal balance between
sensitivity and specificity, depending on the availability
of colonoscopies. The choice of other screening tests
(annual or biennial SOHg determination, sigmoidoscopy
every 5 years or colonoscopy every 10 years) might be
warranted if resources are available (Grade B).
• Individuals included in higher-risk groups (polyposis,
etc.) must be identified, that they may benefit from
specific screening and supervision measures (Grade A).
Lung cancer
According to the latest update of the GLOBOCAN 2012
study [17], lung cancer in Spain is the second most frequent
cancer in men and the fourth most frequent cancer in
women. Lung cancer is the third most frequent carcinoma
if we combine the data for both sexes (26,700 cases in
2012, with a mortality rate of 21,118). This accounts for
20 % of all cancer deaths in Spain. Data for the US indicate
that lung cancer is the main cause of early death from
cancer in that country, with an estimated cost of 2.37
million years of life in 2010 [18].
These data reveal the importance of lung cancer pre-
vention. If we bear in mind that the most important factor
involved in the development of the disease—cigarette
smoking—is clearly identified, neglect of preventive
measures is inexcusable.
In recent years, different randomised studies [19, 20]
have examined the potential value of low-dose computer-
ised tomography in the prevention of lung cancer. These
studies have revealed that the yearly performance of CT
scans in high-risk groups (that is, individuals of
55–74 years of age who are active smokers or gave up the
habit \15 years previously, with a history of at least 30
pack years) can decrease lung cancer mortality rates by
20 %, as compared to annual chest X-rays, with no added
collateral damages resulting from radiological exposure
[21].
Apart from the recommendation of yearly TC scans in
high-risk groups [22], it is crucial to insist that smokers
give up their habit, and to make sure that people who do
not smoke do not begin to do so. Lung cancer screening
should not be regarded as an alternative to giving up
smoking (Table 6).
Table 5 Recommendations for population-wide CRC screening programmes
Recommendation Evidence
CRC screening should be offered to all individuals with no risk factors as from the age of 50. In accordance with guidelines
established in our milieu (European Union, Spain and its regions), SOH detection tests should be performed every 2 years in men
and women of 50–74 years of age
A
Screening tests in population programmes should be based on a quantitative SOHi analysis with a positive cutoff point that
guarantees an optimal balance between sensitivity and specificity, depending on the availability of colonoscopies. The choice of
other screening tests (annual or biennial SOHg determination, sigmoidoscopy every 5 years or colonoscopy every 10 years) might
be warranted if resources are available
B
Individuals included in higher-risk groups (polyposis, etc.) must be identified, that they may benefit from specific screening and
supervision measures
A
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Finally, it is essential that screening tests for lung cancer
are personally discussed with all potential candidates, and
carried out by multidisciplinary teams made up of experts
in the management and treatment of the disease.
Conclusions
Improved rates of cure for cancer are due in recent years to
improvements in treatment and to the implementation of
prevention programmes.
In some types of cancer, primary and secondary pre-
vention measures can have a very significant effect on the
reduction of incidence rates, and on the increase of survival
as a result of earlier detection and diagnosis.
It is indispensable to encourage research into further
prevention measures, especially in tumours whose rates of
survival are the lowest.
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